Q1 2025 Kymera Therapeutics Inc Earnings Call Transcript

May 9, 2025 / 02:00 PM GMT

Release Date Price: $30.07 (-2.27%)

Transcript 10-Q8-K

Key Points

Positve

Kymera Therapeutics Inc (KYMR) has a strong financial position with $775 million in cash, extending their runway into the first half of 2028.
The company has successfully brought five new molecules into the clinic since 2020, with plans to deliver ten by 2026.
Kymera Therapeutics Inc (KYMR) is a leader in targeted protein degradation, a novel modality that offers oral drugs with biologics-like efficacy.
The company has a robust pipeline with multiple upcoming clinical data readouts, including the Stat 6 program, which is expected to transform treatment paradigms for TH2 allergic diseases.
Kymera Therapeutics Inc (KYMR) has achieved a $20 million milestone payment from Sanofi for their KT 474 program, validating their strategy and collaboration efforts.

Negative

The company decided not to advance their T2 degrader KT295 into clinical development, citing resource allocation priorities.
There is a highly competitive landscape in the T2 space, which influenced the decision to pause the T2 program.
The company faces challenges in ensuring accurate degradation kinetics measurement, as seen in previous studies with variability in results.
Kymera Therapeutics Inc (KYMR) acknowledges the volatile market environment, which requires careful resource management and prioritization.
The development of the IRF 5 program is still in early stages, with clinical trials expected to start in early 2026, indicating a longer timeline before potential commercialization.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

KYMR.OQ - Kymera Therapeutics Inc
Q1 2025 Kymera Therapeutics Inc Earnings Call
May 09, 2025 / 02:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning and welcome to Chimera's Immunology Innovation Day, our virtual event to introduce our next immunology program, IRA 5. I'm Justine Konigsberg, Chimera's head of investor relations. Please note that we are hosting today's event in lieu of our regularly scheduled quarterly update call. However, we have reported our results and filed our 10 this morning. For additional details and on our Q1 results, please reference our press release issued this morning, which is available in the IR section of our website.

During today's presentation, you'll hear from our team about our strategy, our pipeline advancements, and our next high-value immunology program.

Joining me this morning are Nelo Minolfi, our

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.